project id: TCGA-CESC; case submitter id: TCGA-DG-A2KH; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.8; rna integrity number: 8.6; age at index: 25; days to birth: -9209; ethnicity: not reported; gender: female; race: not reported; vital status: Alive; age at diagnosis: 9209; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic t: T1b1; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 34.0; figo stage: Stage IB1; icd 10 code: C53.9; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 120.0; portion submitter id: TCGA-DG-A2KH-01A-21; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 10.0; percent necrosis: 10.0; percent neutrophil infiltration: 30.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;